Almonertinib (hydrochloride)
Product Sizes
5 mg
£ POA
HY-112823B-5MG
25 mg
£ POA
HY-112823B-25MG
50 mg
£ POA
HY-112823B-50MG
100 mg
£ POA
HY-112823B-100MG
10 mg
£ POA
HY-112823B-10MG
10mM/1mL
£ POA
HY-112823B-10MM
About this Product
- SKU:
- HY-112823B
- Additional Names:
- HS-10296 (hydrochloride)
- CAS Number:
- 2134096-03-8
- Extra Details:
- Almonertinib (HS-10296) hydrochloride is an orally available; irreversible; third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M; T790M/L858R and T790M/Del19 (IC50: 0.37; 0.29 and 0.21 nM; respectively); and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer[1][2].
- Molecular Weight:
- 562.11
- Purity:
- 98.92
- References:
- [1]Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76.|[2]Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.|[3]Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0864(20)30714-0.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- 4[o]C (Powder; sealed storage; away from moisture)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
